Sterility assurance of microspheres

Area of Science:

• Pharmaceutical Science
• Regulatory Science
• Drug Development

Background:

• The International Council for Harmonisation (ICH) facilitates dialogue between regulatory bodies and the pharmaceutical industry.
• ICH guidelines aim to harmonize technical requirements for drug registration across the EU, US, and Japan.
• Cultural and legal differences impact guideline interpretation, particularly between the US and Japan.

Purpose of the Study:

• To highlight the need for flexible interpretation of ICH guidelines in Japan for new dosage forms.
• To introduce a method for assuring the sterility of a novel pharmaceutical product.
• To present the pharmaceutical development of once-monthly injectable, biodegradable microspheres of Leuprorelin.

Main Methods:

• Focus on the sterility assurance strategy for a specific new dosage form.
• Detailed explanation of the development process for Leuprorelin biodegradable microspheres.
• Case study of pharmaceutical development at Takeda Chemical Industries.

Main Results:

• The study introduces a practical approach to ensuring sterility for a complex dosage form.
• Demonstrates successful pharmaceutical development of a once-monthly injectable Leuprorelin product.
• Provides insights into navigating regulatory differences for drug registration.

Conclusions:

• A flexible, science-based approach to ICH guidelines is crucial for pharmaceutical innovation in Japan.
• Effective sterility assurance is paramount for novel injectable dosage forms.
• The development of Leuprorelin biodegradable microspheres exemplifies successful adaptation to regional regulatory nuances.